Home › NDC Lookup › RxCUI directory › RxCUI 2714251

Telisotuzumab vedotin-tllv 100 MG Injection [Emrelis] — RxCUI 2714251

RxNorm drug concept · Semantic branded drug
RxCUI 2714251 Semantic branded drug · SBD ● Current RxNorm concept 2 FDA products 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2714251
Official nameTelisotuzumab vedotin-tllv 100 MG Injection [Emrelis]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asEmrelis 100 MG Injection
FDA products mapped2
Package NDCs mapped2
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

🕸️ Concept Web — How Telisotuzumab vedotin-tllv 100 MG Injection [Emr... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Telisotuzumab vedotin-tllv 100 MG Injection [Emrelis] RxCUI 2714251

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Telisotuzumab 2714237
    • Telisotuzumab vedotin-tllv 2714236
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Emrelis 2714246
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Telisotuzumab Injection 2714242
    • Telisotuzumab vedotin-tllv Injection 2714244
    • Telisotuzumab Injectable Product 2714241
    • Telisotuzumab vedotin-tllv Injectable Product 2714243
    • Telisotuzumab Injection [Emrelis] 2714249
    • Telisotuzumab vedotin-tllv Injection [Emrelis] 2714250
    • Emrelis Injectable Product 2714248
    • Injection 1649574
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 14 of 15 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Telisotuzumab vedotin-tllv 100 MG Injection SCD · 2714245
  • Telisotuzumab vedotin-tllv 100 MG SCDC · 2714240
  • Telisotuzumab Injection SCDF · 2714242
  • Telisotuzumab vedotin-tllv Injection SCDFP · 2714244
  • Telisotuzumab Injectable Product SCDG · 2714241
  • Telisotuzumab vedotin-tllv Injectable Product SCDGP · 2714243

Brand-Name Concepts

  • Telisotuzumab vedotin-tllv 100 MG [Emrelis] SBDC · 2714247
  • Telisotuzumab Injection [Emrelis] SBDF · 2714249
  • Telisotuzumab vedotin-tllv Injection [Emrelis] SBDFP · 2714250
  • Emrelis Injectable Product SBDG · 2714248
  • Emrelis BN · 2714246

📦 FDA Products & Package NDCs

2 products · 2 package NDCs
2 package NDCs map to RxCUI 2714251 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00074-1044-01 1 VIAL, SINGLE-DOSE in 1 CARTON (0074-1044-01) / 1 mL in 1... EMRELIS AbbVie Inc. 2025-05-14
00074-1055-01 1 VIAL, SINGLE-DOSE in 1 CARTON (0074-1055-01) / 1 mL in 1... EMRELIS AbbVie Inc. 2025-05-14
Observed labelers: AbbVie Inc. (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🧾 Billing Codes (HCPCS)

Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.
CodeDescriptorMapped packagesSources
J9326 Telisotuzumab vedotin-tllv 2 CMS
⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.